Nephron and Clemson to Develop Robotics for Syringe Filling
Nephron Pharmaceuticals is partnering with Clemson University to create a robotic solution for syringe-filling automation to enhance sterile manufacturing.
Nephron Pharmaceuticals Corporation, which is based in West Columbia, SC, announced on Aug. 12, 2019, that the company is partnering with Clemson University to create a robotic solution for syringe-filling automation. The robotics research is being done to enhance sterile manufacturing to keep up with supply demand. The technology will support the Nephron 503B Outsourcing Facility, a cGMP manufacturer providing sterile, prefilled medications.
The partnership is Nephron's first with the University and was developed through External Affairs' Office of Corporate Partnerships and Strategic Initiatives at Clemson. "Industry needs are changing at a rapid rate, and Clemson is equipped to support companies like Nephron. Together, we have created a mutually beneficial project to enhance their capabilities while providing the University's students with unique, hands-on research experience," said Angie Leidinger, vice-president for External Affairs, in the press release.
Clemson College of Engineering, Computing, and Applied Science professor and researcher Yue "Sophie" Wang, mechanical engineering doctoral student Brandon Delspina, and mechanical engineering master's student Yu "Gloria" Zhang are performing the robotics research.
Source: Nephron
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
